Overview
Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug. It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. This drug works by modifying the tumor microenvironment and increasing intratumoral chemotherapy penetration and T-cell infiltration. NGR-hTNF specifically targets angiogenic tumor blood vessels using the NGR motif. Literature demonstrates that NGR-peptides bind to a CD13 isoform, of which expression is restricted to tumor vasculature cells. A study also demonstrated that binding of the NGR-motif to CD13 determined both the homing of NGR-hTNF to tumor vessels and the increase in its antiangiogenic activity.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2019/01/15 | Phase 2 | Completed | AGC Biologics S.p.A. | ||
2018/05/24 | Phase 2 | Completed | Andres J. M. Ferreri | ||
2011/05/23 | Phase 2 | Completed | AGC Biologics S.p.A. | ||
2011/05/23 | Phase 2 | Completed | AGC Biologics S.p.A. | ||
2010/04/02 | Phase 3 | Completed | AGC Biologics S.p.A. | ||
2009/10/14 | Phase 2 | Completed | AGC Biologics S.p.A. | ||
2009/04/08 | Phase 1 | Completed | AGC Biologics S.p.A. | ||
2008/05/08 | Phase 2 | Completed | AGC Biologics S.p.A. | ||
2007/06/08 | Phase 2 | Completed | AGC Biologics S.p.A. | ||
2007/06/08 | Phase 2 | Completed | AGC Biologics S.p.A. |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.